Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized study of Rupatifen Fumarate Capsules in seasonal allergic rhinitis
ChiCTR2600128435Phase 3Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rupatadine in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Change from baseline in average reactive total nasal symptom score (rTNSS) during treatment period (Day 1–15). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
rupatadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2600128435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128435.